title: A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.
abstract: Data compiled from computer-generated summaries of patient records submitted to Hoechst-Roussel Pharmaceuticals were reviewed regarding the efficacy and toxicity of cefotaxime in the therapy of skin and skin structure infections associated with gram-positive pathogens. In addition, published open and comparative trials employing cefotaxime in gram-positive and gram-negative skin infections were evaluated with respect to the pathogens isolated and the nature, severity and bacteriological and clinical outcome of the treated infections. Within the limitations of the data reviewed, cefotaxime appeared to be a safe and effective therapy in greater than 90% of infections including cellulitis, abscesses and necrotizing ulcers of the skin and subcutaneous tissues when associated with the isolation of susceptible gram-negative bacilli, methicillin-susceptible Staphylococcus aureus, or aerobic or anaerobic gram-positive pathogens susceptible to aqueous penicillin G. The data would indicate that cefotaxime is a suitable therapy for patients with presumed polymicrobial, non-crepitant infections of the skin or skin structures pending microbiological studies. However, cefotaxime cannot be recommended for similar infections due to organisms such as methicillin-resistant S. aureus or Pseudomonas aeruginosa that are commonly resistant to cefotaxime in vitro. Data regarding skin and skin structure infections associated with Clostridium spp. and enterococcal group D streptococci are either lacking or inconclusive with respect to the utility of cefotaxime.
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000009:adverse effects / Q000627:therapeutic use*; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D012874:Skin Diseases, Infectious / Q000188:drug therapy*
chemical_list: D002439:Cefotaxime